Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial

BACKGROUND: No novel chemotherapeutic combinations have demonstrated superior efficacy to etoposide/cisplatin (EP), a standard treatment regimen for extensive-stage small cell lung carcinoma (ES-SCLC) over the past decade. We aimed to compare the efficacy and safety of belotecan/cisplatin (BP) and E...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, In-Jae, Kim, Kyu-Sik, Park, Cheol-Kyu, Kim, Young-Chul, Lee, Kwan-Ho, Jeong, Jin-Hong, Kim, Sun-Young, Lee, Jeong-Eun, Shin, Kye-Chul, Jang, Tae-Won, Lee, Hyun-Kyung, Lee, Kye-Young, Lee, Sung-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002146/
https://www.ncbi.nlm.nih.gov/pubmed/27566413
http://dx.doi.org/10.1186/s12885-016-2741-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002146/
https://www.ncbi.nlm.nih.gov/pubmed/27566413
http://dx.doi.org/10.1186/s12885-016-2741-z

Ejemplares similares